GEN Exclusives

More »

Feature Articles

More »
Sep 1, 2009 (Vol. 29, No. 15)

Searching for Appropriate Cancer Biomarkers

Tumor-Specific Antigens Could Positively Impact Diagnosis, Imaging, and Therapy

  • Click Image To Enlarge +
    Cyanobacteria has developed an extensive carbohydrate coating to protect it against extreme temperature and dryness.

    The medical literature abounds with examples of the benefits of early cancer detection. Cure rates are always dramatically higher before the tumor has spread and while surgery is still an option. For example in cervical cancer, detection at the earliest stages of the disease is associated with a 99% five-year survival rate. Similarly encouraging statistics may be found for cancers of the breast, ovaries, colon, skin, and other sites.

    Cancer detected through physical examination or medical imaging is usually too advanced for hope of a cure, which has led to an explosion of research into molecular diagnostics. Immunoassays, the leading category of such tests, are exquisitely sensitive and have the potential to diagnose cancer at the stage of just a few cells. Unfortunately commercial molecular diagnostics for cancer suffer from a lack of specificity, sensitivity, and overall robustness.

  • An Ounce of Prevention

    Cancer biomarker discovery has been hampered by the heterogeneity of the diseases known as cancer. Even within one cancer type, for example breast, several distinct clinical types exist; moreover, within these researchers have found dozens of genotypic differences. Despite these challenges, the search goes on for these important diagnostic tools.

    Once cancer biomarkers are discovered and approved, their dissemination among medical specialists is relatively uncontrolled. Three cancer markers that immediately come to mind are prostate-specific antigen (PSA) for prostate cancer, CA-125 for ovarian malignancies, and HER2-neu in breast cancer.

    PSA is found in normal prostate tissue and at elevated levels when the gland is inflamed. Since PSA is not specific to prostate malignancy, diagnosis of prostate cancer based on rising PSA serum levels results in a high rate of false positives—up to 75% according to some studies. False positives are highly undesirable because they trigger costly, invasive medical interventions that divert healthcare resources that could be better spent.

    Biopsies of 100 suspected prostate cancer patients with PSA readings of 3 ng/mL or higher will return only 25 confirmed cases. In addition, 40% of PSA-negative readings are false. PSA was approved by the FDA at a time when prostate cancer diagnostics were essentially nonexistent. Were the PSA test to come up for regulatory review today, it is unlikely it would be approved for prostate cancer screening.

    Diagnostic tests that are approved for one purpose are often applied to situations for which the test was not designed. PSA is a prime example. PSA was originally approved in 1985 as a test for the recurrence of prostate cancer in men who had been treated with radiation or surgery. Today the test is routinely prescribed as a screening tool despite the fact that evidence linking PSA testing to improved outcomes is lacking.

    The U.S. Preventive Services Task Force concluded after reviewing the literature that it would take 1,000 PSA screenings to prevent one death from prostate cancer. At the same time the numerous false positives and inconclusive results would subject hundreds of these men to unnecessary interventions that include biopsies, surgery, and medical treatment, not to mention the anxiety of uncertainty regarding their health status.

    Clearly a useful cancer test will possess high diagnostic specificity and sensitivity, be expressed exclusively by tumors of one type, and detect cancer early to provide a reasonable hope of cure. The ability to predict both outcomes and response to therapy could be considered added benefits.


Readers' Comments

Posted 11/20/2009 by Stock Trader

Have read the above letter which leads to some confusion to a medical lay person. Is the company now profitable with other products. When is there a light as to when the company will have working products?

Posted 11/17/2009 by Buy or?

It seems to me that they are working at an enlightening of common theory and insistence on treatinga ll cancers in a group the same. What about the prevention if you are finding antibodies to attack, why not prevention and intervention.

Posted 10/12/2009 by future share holder

This is huge discovery but I wonder if now is the time to buy MBCI or if another company will advance their work and be the big winner?
Any comments ?

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?